In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria

Journal of Antibiotics

Volumn 68, Issue 6, 2015, Pages 395-398

  Kim, Kwang Sun ^a,b   Kim, Taeyeon ^a   Pan, Jae Gu ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROX; POLYMYXIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; PYRIDONE DERIVATIVE;

ACINETOBACTER BAUMANNII; ADJUVANT THERAPY; ARTICLE; DRUG EFFICACY; DRUG POTENTIATION; ESCHERICHIA COLI; EVALUATION STUDY; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; AGONISTS; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

NEGIBACTERIA;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PYRIDONES;

EID: 84933505350     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2014.164     Document Type: Article

References (20)

1. Falagas, M. E. & Kasiakou, S. K. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40, 1333-1341 (2005).
2. Nakajima, S. Clinical use of colimycin F otic solution. Jibiinkoka 37, 693-697 (1965).
3. Ohzawa, R. The use of colimycin ear drops. Jibiinkoka 37, 585-590 (1965).
4. Gordon, N. C., Png, K. & Wareham, D. W. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 54, 5316-5322 (2010).
5. Tripodi, M. F., Durante-Mangoni, E., Fortunato, R., Utili, R. & Zarrilli, R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 30, 537-540 (2007).
6. Wareham, D. W. & Bean, D. C. In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 50, 825-826 (2006).
7. Subissi, A., Monti, D., Togni, G. & Mailland, F. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70, 2133-2152 (2010).
8. Hoque,M. et al. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6, 90 (2009).
9. Lee,S.J.et al. Ciclopirox protects mitochondria from hydrogen peroxide toxicity. Br. J. Pharmacol. 145, 469-476 (2005).
10. Ko, S. H. et al. Antimycotic ciclopirox olamine in the diabetic environment promotes angiogenesis and enhances wound healing. PLoS One 6, e27844 (2011).
11. Carlson-Banning, K. M. et al. Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae. PLoS ONE 8, e69646 (2013).
12. Huttner, B. et al. Drugs of last resort? The use of polymyxins and tigecycline at US veterans affairs medical centers, 2005-2010. PLoS One 7, e36649 (2012).
13. Elipoulos G. M. & Moellering R. C. in Antibiotic in Laboratory Medicine 4th edn (ed. Lorian, V.) 330-396 (William and Wilkins Baltimore, MD, 1996).
14. Dong, X. et al. In vitro activities of rifampicin, colistin, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J. Antibiot. 67, 677-680 (2014).
15. Yoon, J., Urban, C., Terzian, C., Mariano, N. & Rahal, J. J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrugresistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48, 753-757 (2004).
16. Wareham, D. W. & Bean, D. C. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann. Clin. Microbiol. Antimicrob 5, 10 (2006).
17. Tadesse, D. A. et al. Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950-2002. Emerg. Infect. Dis. 18, 741-749 (2012).
18. Zhai, B. et al. Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect. J. Antimicrob. Chemother. 65, 931-938 (2010).
19. Minden, M. D. et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. Am. J. Hematol. 89, 363-368 (2014).
20. Stevenson, G. et al. Structure of the O antigen of Escherichia coli K-12 and the sequence of its rfb gene cluster. J. Bacteriol. 176, 4144-4156 (1994).